2025年9月9日已获百慕大注册署批准，将领航医药生物科技有限公司改名为：Starcoin Group, Ltd.(星太 链集团有限公司)。 ...

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the announcement that its placement agreement for up to 145 million new shares, aimed at raising HKD 60.18 million, has lapsed due to unmet conditions by September 11 [1] Group 1: Company Announcement - Pioneer Pharma announced that the placement agreement has become invalid, but the board believes this will not have a significant adverse impact on the company's current operations and financial status [1] - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1] Group 2: Market Reaction - As of the report, Pioneer Pharma's stock price fell by 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1]

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the expiration of a share placement agreement aimed at raising HKD 60.18 million, which failed to meet its conditions by the deadline of September 11 [1] Group 1: Stock Performance - As of the report, Pioneer Pharma's stock is down 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1] Group 2: Share Placement Agreement - The company announced that the share placement agreement for a maximum of 145 million new shares has become invalid due to unmet conditions [1] - The board believes that the failure of the placement agreement will not have any significant adverse impact on the company's current operations and financial status [1] Group 3: Previous Announcements - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1]

Group 1 - The company, Pioneer Pharma Biotech (00399), announced a share placement at a price of HKD 0.415 per share, with a maximum of 145 million shares to be placed [1] - The placement agreement has become invalid as the conditions precedent were not met by September 11, 2025, and the placement will not proceed [1] - All responsibilities under the placement agreement between the placement agent and the company will terminate, and no claims can be made by either party regarding the placement agreement [1]

Group 1 - The company announced that the previously planned placement of up to 145 million shares at HKD 0.415 per share has become invalid [1] - The reason for the invalidation is that the conditions precedent of the agreement were not met by September 11, 2025 [1] - As a result, the placement will not proceed, and both the placement agent and the company have terminated their responsibilities under the agreement, with no claims allowed between the parties [1]

格隆汇9月11日丨领航医药生物科技(00399.HK)公告，内容有关公司与中国北方证券集团有限公司（作 为配售代理）所订立日期为2025年8月21日的配售协议，以按配售价每股配售股份0.415港元认购最多 1.45亿股公司配售股份。董事会宣布，由于配售协议所载的先决条件未能于2025年9月11日或之前达 成，配售协议已失效且配售事项将不会进行。 ...

领航医药生物科技(00399)公布，就按配售价每股配售股份0.415港元配售最多1.45亿股公司配售股份， 由于配售协议所载的先决条件未能于2025年9月11日或之前达成，配售协议已失效且配售事项将不会进 行。配售代理及公司于配售协议项下的所有责任将告终止及终结，且任何订约方概不得就配售协议向另 一方提出任何申索。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 根據一般授權配售新股份失效 配售代理 CNI SECURITIES GROUP 中国北 方证券集团 茲 提 述 領 航 醫 藥 及 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 八 月 二十一日及二零二五年八月二十九日的公告，內容有關（其中包括）本公司與 中 國 北 方 證 券 集 團 有 限 公 司（作 為 配 售 代 理）所 訂 立 日 期 為 二 零 二 五 年 八 月 二十一日的配售協議，以按配售價每股配售股份0.415港元認購最多145,000,000 股本公司配售股份（「該等公告」）。除另有指明外，本公告所用詞彙與該等公告 所界定者具有相同涵義。 董事會宣佈，由於配售協議所載 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 領航醫藥生物科技有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00399 | 說明 | 領航醫藥生物科技 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 50,000,000,000 | HKD | | 0.01 | HKD | | 500,000,0 ...

Group 1 - The latest shareholder equity disclosures for three companies: Vanguard Medical Biotechnology (00399), Huaxin Cement (06655), and CSPC Pharmaceutical Group (01093) were made on September 3, 2025 [1] Group 2 - Vanguard Medical Biotechnology: - Shareholder Mao Yumin reduced holdings from 1.55 billion shares to 1.50 billion shares, holding percentage decreased from 72.33% to 70.00% [2] - Huaxin Cement: - Shareholder Li Yeqing increased holdings from 454,000 shares to 508,600 shares, holding percentage increased from 0.03% to 0.04% [2] - CSPC Pharmaceutical Group: - Shareholder Cai Xin increased holdings from 50,000 shares to 100,000 shares, holding percentage remained at 0% [2]